Clinical picture of envenoming with the Meadow Viper (Vipera(Acridophaga)ursinii)

Krecsák, László; Zacher, Gábor; Malina, Tamás

doi:10.3109/15563650.2010.550049

Cited by 14 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vipera ursinii is generally considered to be the least medically significant species of the genus Vipera, mainly because of the limited amount of venom it can inject and the typically very mild and local envenomation symptoms it can cause (Dely and Joger 2005;Krecsak et al, 2011). The venom of this species has been reported to cause haemorrhagic effects in mice, but no myotoxicity (Mebs and Langeluddeke 1992).…”

Section: Vipera Ursiniimentioning

confidence: 99%

Vipers of Major clinical relevance in Europe: Taxonomy, venom composition, toxicology and clinical management of human bites

Nicola¹,

Pontara

Kass

et al. 2021

Toxicology

View full text Add to dashboard Cite

Section: Vipera Ursiniimentioning

confidence: 99%

Vipers of Major clinical relevance in Europe: Taxonomy, venom composition, toxicology and clinical management of human bites

Nicola¹,

Pontara

Kass

et al. 2021

Toxicology

View full text Add to dashboard Cite

“…Considering that Europe has a relatively high number of Vipera species with relevant medical aspects, and that Europe shows the most favourable habitat, the underestimation is even greater, confirming the fact that snakebite in Europe is a disease with neglected incidence, morbidity and mortality. This is also justified by the fact that sporadic individual case reports and case series are found in the literature 4–81 …”

Section: Introductionmentioning

confidence: 99%

Vipera snakebite in Europe: a systematic review of a neglected disease

Paolino

Nicola²,

Pontara

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

In 2009, snakebites were included in the list of the World Health Organization (WHO) neglected diseases. Dermatological literature lacks current and up-to-date articles about snakebites and their management, despite the fact that dermatologists, especially from rural hospitals, can be called into the emergency room to consult the management of suspected snakebites. In this systematic review, we highlighted the main clinical and laboratory aspects of snakebites from Vipera spp. in Europe, by reviewing 3574 studies initially retrieved from PubMed, Embase and Cochrane CENTRAL databases. Of these, 78 were finally included in the systematic review. We found that the most involved taxon was V. berus in 63.3% and the most involved anatomic site of the bite was the upper limbs 53.1% with fang marks reported in 90.5%. The mean age of the patients was 32.9 years, and bites were slightly more common among males (58.2%). A wound washing was performed in 86.9% of cases before the hospitalization. The most frequently reported grade of envenomation was G2 (42.2%). In addition to local dermatological symptoms (extended erythema, oedema, cutaneous necrosis, hives, purpura, petechiae, acute compartment syndrome), numerous systemic symptoms have also been reported, including fatigue (14.4%), pain (75.3%), fever (49.2%), direct anaphylactoid reaction (5.3%), anxiety (60.8%), cranial nerve neurotoxicity (14.8%), dysesthesia/paraesthesia (7.9%), vomiting (33.7%), abdominal pain (23.3%), diarrhoea (15.4%), dyspnoea (6.3%), proteinuria (10.6%) and haematuria (9.3%). Secondary infections were present in 3.5% and disseminated intravascular coagulation in 3.1% of cases, and fasciotomy was performed in 4.2% cases, while an amputation in 6.9%. Only 0.9% of patients died. Antivenom was administered in 3053 cases. In conclusion, there is a pressing need for robust multi-centre randomized control trials, standardized protocol for snakebite management and antivenom administration across Europe and a National snakebite register for each European country.

show abstract

“…They can be grouped into seven protein families: snake venom metalloproteinase (SVMP), snake venom serine protease (SVSP), sPLA 2 , cysteine-rich secretory protein (CRISP), snake C-type lectin-like protein (snaclec), Kunitz-type serine protease inhibitor (KSPI) and venom nerve growth factor (VNGF) family (Table S1). No proteins could be identified in Spots 4,6,8,9,40,49 and 50, due either to too low amounts of material or to the lack of similar/identical sequences in the protein database used to search the MS spectra. The most abundant were proteins of 50 kDa belonging to the SVMPs that constituted 1-DE Bands 1 to 4 and 8 (corresponding to 2-DE Spots 11 to 20), and 2-DE Spots 1 to 5, 10 and 23 to 25.…”

Section: Immunological Cross-reactivity Between V Ursinii Ssp and Vmentioning

confidence: 99%

“…In addition, the snake has very short fangs (2-3 mm) through which it can inject only minute amounts of venom (1-4 mg). Accordingly, the symptoms reported in patients envenomed by the V. ursinii venom have been very mild and local, and were resolved spontaneously without medical intervention [8]. ) is a short, light grey or brownish snake characterized by a dark zigzag pattern along its back.…”

Section: Introductionmentioning

confidence: 99%

Biological Activities and Proteomic Profile of the Venom of Vipera ursinii ssp., a very Rare Karst Viper from Croatia

Balija

Leonardi

Brgles

et al. 2020

Toxins

View full text Add to dashboard Cite

The karst viper (Vipera ursinii ssp.) favours high-mountain dry grasslands in southern and south-eastern Croatia. It is medically less important than other Vipera species, because of its remote habitat and the very small amount of venom that it injects by its relatively short fangs. The scientific literature on Vipera ursinii deals mostly with the morphology, ecology and distribution range of this snake, due to the species’ conservation issues, while the toxinological aspects of its venom have not so far been investigated. Here we report on the composition and biological activity of the Vipera ursinii ssp. venom. Using a proteomics approach, we have identified 25 proteins in the venom that belong to seven protein families: snake venom metalloproteinase, serine protease, secreted phospholipase A2, cysteine-rich secretory protein, snake C-type lectin-like protein, serine protease inhibitor and nerve growth factor. The Vipera ursinii ssp. venom was found to be distinctively insecticidal. Its lethal toxicity towards crickets was more than five times greater than that of Vipera ammodytes ammodytes venom, while the opposite held in mice. Interestingly, the mode of dying after injecting a mouse with Vipera ursinii ssp. venom may suggest the presence of a neurotoxic component. Neurotoxic effects of European vipers have so far been ascribed exclusively to ammodytoxins and ammodytoxin-like basic secreted phospholipases A2. Structural and immunological analyses of the Vipera ursinii ssp. venom, however, confirmed that ammodytoxin-like proteins are not present in this venom.

show abstract

Clinical picture of envenoming with the Meadow Viper (Vipera(Acridophaga)ursinii)

Cited by 14 publications

References 12 publications

Vipers of Major clinical relevance in Europe: Taxonomy, venom composition, toxicology and clinical management of human bites

Vipers of Major clinical relevance in Europe: Taxonomy, venom composition, toxicology and clinical management of human bites

Vipera snakebite in Europe: a systematic review of a neglected disease

Biological Activities and Proteomic Profile of the Venom of Vipera ursinii ssp., a very Rare Karst Viper from Croatia

Contact Info

Product

Resources

About